Grant: Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
McMaster University
$100,000.00
Structural Basis of Cyclic Nucleotide Signal Translation and Inhibition
FY 2022-23
Summary
High blood pressure is a major risk factor for stroke and is often caused by miscommunication between cells due to defective signaling by a messenger molecule, cyclic guanosine monophosphate (cGMP). Dysfunctional cGMP signaling also results in life-threatening ruptures of blood vessels, and retinal degeneration causing blindness. In addition, defective reading of the closely related cyclic adenosine monophosphate (cAMP) causes a general predisposition for pancreatic, endocrine, and cardiac tumors as well as intellectual disabilities and abnormal bone growth in children. The long-term goal of this project is to study two proteins involved in cell signaling that bind cGMP and cAMP, protein kinases G (PKG) and A (PKA), and to elucidate the structural and dynamical changes caused by disease-causing mutations that lead to incorrect translation of the cGMP and cAMP signals. We will investigate how drug leads currently in development for such diseases work. For example, pharmacological nitroxyl (HNO) donors effectively reduce blood pressure by mimicking the effect of cGMP on PKG, and cGMP analogs that inhibit PKG are promising drug leads against retinal degeneration, an otherwise uncurable disease. However, further mechanistic understanding is needed to improve current treatments. To this end, we will rely on nuclear magnetic resonance (NMR) spectroscopy. NMR is ideally suited to reveal how cAMP, cGMP, their analogs, and HNO donors modify the structure and dynamics of PKA and PKG, which is needed to understand how to modulate these proteins' activities. NMR is also ideal for unveiling how disease-causing inherited mutations alter PKA's and PKG's reading of cAMP and cGMP signals, respectively. Understanding the structural and dynamical changes caused by these disease-related mutations and drug leads will reveal the molecular origins of multiple cardiovascular diseases, tumors, pediatric disorders, and retinal degeneration and will enable the design of improved treatments.
Department
Program
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
483395
Name
Melacini Giuseppe
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Biochemistry & Molecular Biology - A
Projecttitle
Structural Basis of Cyclic Nucleotide Signal Translation and Inhibition
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Keyworddelim
Acrodysostosis; Allostery; Aneurysm; Carney Complex; Cyclic Nucleotides; Dynamics; Nuclear Magnetic Resonance (Nmr); Protein Kinase; Retinal Degeneration; Signaling
Abstract
High blood pressure is a major risk factor for stroke and is often caused by miscommunication between cells due to defective signaling by a messenger molecule, cyclic guanosine monophosphate (cGMP). Dysfunctional cGMP signaling also results in life-threatening ruptures of blood vessels, and retinal degeneration causing blindness. In addition, defective reading of the closely related cyclic adenosine monophosphate (cAMP) causes a general predisposition for pancreatic, endocrine, and cardiac tumors as well as intellectual disabilities and abnormal bone growth in children. The long-term goal of this project is to study two proteins involved in cell signaling that bind cGMP and cAMP, protein kinases G (PKG) and A (PKA), and to elucidate the structural and dynamical changes caused by disease-causing mutations that lead to incorrect translation of the cGMP and cAMP signals. We will investigate how drug leads currently in development for such diseases work. For example, pharmacological nitroxyl (HNO) donors effectively reduce blood pressure by mimicking the effect of cGMP on PKG, and cGMP analogs that inhibit PKG are promising drug leads against retinal degeneration, an otherwise uncurable disease. However, further mechanistic understanding is needed to improve current treatments. To this end, we will rely on nuclear magnetic resonance (NMR) spectroscopy. NMR is ideally suited to reveal how cAMP, cGMP, their analogs, and HNO donors modify the structure and dynamics of PKA and PKG, which is needed to understand how to modulate these proteins' activities. NMR is also ideal for unveiling how disease-causing inherited mutations alter PKA's and PKG's reading of cAMP and cGMP signals, respectively. Understanding the structural and dynamical changes caused by these disease-related mutations and drug leads will reveal the molecular origins of multiple cardiovascular diseases, tumors, pediatric disorders, and retinal degeneration and will enable the design of improved treatments.
Competitiondate
202303
Approvedterm2
1 yr 0 mth
Pinamesdelim
Melacini, Giuseppe
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~